Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | IKEMA: kD vs isatuximab and kD in R/R myeloma

Philippe Moreau • 16 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Carfilzomib Dexamethasone Isatuximab
IKEMA

Philippe Moreau, MD, Nantes University Hospital, Nantes, France, discusses the Phase III IKEMA study (NCT03275285), investigating isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Philippe Moreau

1:15
Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau • 15 Feb 2023
4:49
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy
Philippe Moreau • 15 Feb 2023
3:02
Optimal treatment strategies for multiple myeloma
Philippe Moreau • 10 Sep 2021
1:59
Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau • 10 Sep 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals